惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

博客园 - Franky
有赞技术团队
有赞技术团队
宝玉的分享
宝玉的分享
雷峰网
雷峰网
Hugging Face - Blog
Hugging Face - Blog
V
V2EX
大猫的无限游戏
大猫的无限游戏
博客园 - 司徒正美
D
Docker
T
The Blog of Author Tim Ferriss
罗磊的独立博客
博客园 - 叶小钗
酷 壳 – CoolShell
酷 壳 – CoolShell
Blog — PlanetScale
Blog — PlanetScale
月光博客
月光博客
J
Java Code Geeks
Jina AI
Jina AI
博客园 - 【当耐特】
C
Check Point Blog
OSCHINA 社区最新新闻
OSCHINA 社区最新新闻
腾讯CDC
Last Week in AI
Last Week in AI
freeCodeCamp Programming Tutorials: Python, JavaScript, Git & More
V
Visual Studio Blog

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Fulcrum Therapeutics, Inc. (FULC) Q1 2026 Earnings Call T...
SA Transcripts · 2026-04-27 · via All Articles on Seeking Alpha

Q1: 2026-04-27 Earnings Summary

EPS of -$0.25 beats by $0.05

 | 

Revenue of

$0.00

beats by $0.00

Fulcrum Therapeutics, Inc. (FULC) Q1 2026 Earnings Call April 27, 2026 8:00 AM EDT

Company Participants

Alexander Sapir - CEO, President & Director
Alan Musso - Chief Financial Officer
Iain Fraser - Senior Vice President of Early Development

Conference Call Participants

Joseph Schwartz - Leerink Partners LLC, Research Division
Anupam Rama - JPMorgan Chase & Co, Research Division
Kristen Kluska - Cantor Fitzgerald & Co., Research Division
Corinne Jenkins - Goldman Sachs Group, Inc., Research Division
James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division
Matthew Biegler - Oppenheimer & Co. Inc., Research Division
Gregory Renza - Truist Securities, Inc., Research Division

Presentation

Operator

Good morning, and welcome to Fulcrum Therapeutics First Quarter 2026 Financial Results and Business Update Conference Call. [Operator Instructions] This call is being webcast live and can be accessed on the Investors section of Fulcrum's website at www.fulcrumtx.com and is being recorded.

Please be reminded that remarks during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, may include statements about the company's future expectations and plans, clinical development time lines and financial projections.

While these forward-looking statements represent Fulcrum's views as of today, they should not be relied upon as representing the company's views in the future. Fulcrum may update these statements in the future, but is not taking on an obligation to do so. Please refer to Fulcrum's most recent filings with the Securities and Exchange Commission for discussions of certain risks and uncertainties associated with the company's business.

Leading the call today will be Alex Sapir, CEO and President of Fulcrum. Joining Alex on the call are Alan Musso, Chief Financial Officer; and Dr. Iain Fraser, Senior Vice President, Clinical Development. After providing updates on the company's key programs, there will be a brief Q&A in which the Fulcrum management team will be available for questions.